Pathfinder Cell Therapy Inc PFND
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–0.00
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $667.16
- Volume/Avg
- 500 / 3,450
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Pathfinder Cell Therapy Inc is a regenerative medicine company. It is engaged in developing novel cell-based and related therapies for the treatment of diabetes, renal diseases and medical conditions characterized by organ-specific cell damage. Further, the group has discovered a new mammalian cell type, which is able to stimulate damaged tissues to regenerate without the Pathfinder Cells (“PCs”) themselves being incorporated into the new tissue. Geographically the business activities are functioned through the region of United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 1
Valuation
|
Metric
|
PFND
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
PFND
Financial Strength
|
Metric
|
PFND
|
|---|---|
Quick Ratio | 0.00 |
Current Ratio | 0.00 |
Interest Coverage | −2.54 |
Quick Ratio
PFND
Profitability
|
Metric
|
PFND
|
|---|---|
Return on Assets (Normalized) | −1,542.86% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
PFND
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Pjzvpvsxjt | Ykt | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Dkcyrjhpk | Jtwxf | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Kcyptnfl | Gkmxqfq | $99.5 Bil | |
MRNA
| Moderna Inc | Kmgxctc | Jpywk | $38.8 Bil | |
ARGX
| argenx SE ADR | Pscsgvtkl | Qnsd | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Jvmbgfm | Gyjv | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Cgcnjyw | Gwhrds | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Sbcfhskx | Qjmlzw | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Mccrcjphmj | Bpbcsc | $12.5 Bil | |
INCY
| Incyte Corp | Sxdwcrfn | Wswwft | $11.6 Bil |